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Abstract
Background/Objective—To study the effects and safety of cantharidin in the treatment of
molluscum contagiosum.
Methods—We conducted a prospective, double-blinded, placebo-controlled, randomized clinical
trial to evaluate the safety and efficacy of topical cantharidin for treatment of pediatric molluscum
contagiosum in an academic ambulatory care center. Twenty-nine children aged 5–10 with the
diagnosis of molluscum contagiosum were enrolled to receive treatment with cantharidin or
placebo. The main outcome measure was complete clearance of molluscum lesions.
Results—In contrast to previous retrospective observational studies, the performance of
cantharidin treatment over 2 months was not substantially better than the performance of placebo.
Limitations—The scope of follow-up was limited to 5 visits over 2 months of treatment. In
hindsight, we can hypothesize that a longer follow up period may have captured a greater effect of
cantharidin.
Conclusion—We conclude that during a 2 month period, the magnitude of the cantharidin
treatment effects in the target population are, at best, not large. This study provided objective
unbiased estimates of the magnitude of cantharidin treatment effects and provided important
prospective safety data. Our subjects experienced minimal side effects when treated with
cantharidin.
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Molluscum contagiosum (MC) is a dermatologic disorder caused by the molluscum
contagiosum virus (a poxvirus). MC commonly affects children of elementary school age.
The virus is spread through close skin-to-skin contact, and patients can often auto-inoculate
themselves, making MC a dynamic disease within individual patients. Infection can last
from several months to four years.1 Though self-limited, molluscum lesions can be
symptomatic, unsightly, and embarrassing. Parents often seek treatment to decrease
symptoms and improve the appearance. There are several treatment approaches: destructive,
immunologic, antiviral, and active non-intervention. Destructive measures include curettage,
cryotherapy, needle pricking, or topical vesicants such as cantharidin.2,3 Other destructive
approaches include retinoids, silver nitrate, potassium hydroxide, salicylic acid, and
phenols.4–14 Immunologic therapies include imiquimod, nitric oxide, and cimetidine,
although the efficacy of these therapies remains controversial. Antiviral therapies are few,
but cidofovir has been used in adult HIV patients with molluscum contagiosum.15
There is debate about the standard of care for molluscum contagiousm. Due to its self-
limiting nature, treatment options attempt to minimize scarring and other side effects while
speeding recovery time. Care must be taken to find non-traumatic modalities with minimal
pain. Watchful waiting or “active non-intervention” is a practice commonly employed.
However, parents may not be satisfied with waiting for an undetermined period of time that
could last years. Additionally, there still exists the potential for spread to other children.
Cantharidin is a topical vesicant that has been used in the treatment of MC since at least the
1950s. It is an extraction from blister beetles, cantharis vesicatoris, and acts as a protein
phosphatase inhibitor in vitro.16 When applied to the skin, it produces a small intraepidermal
blister that usually heals without scarring.
Recently there have been greater restrictions in the ability of dermatologists to access
preparations of cantharidin. Ambiguity regarding its FDA status has made some academic
institutions leery of condoning its use. However, cantharidin is often cited in dermatology
and pediatric literature as a valuable treatment.3,12,16,17 Unfortunately, there have been no
randomized clinical trials of cantharidin. Our study is the first prospective, placebo-
controlled, randomized trial evaluating the safety and efficacy of cantharidin for pediatric
MC.
Materials and Methods
This prospective, double-blinded, placebo-controlled, randomized clinical trial was designed
to evaluate the safety and efficacy of cantharidin for treatment of pediatric MC. This trial
was registered with http://clinicaltrials.gov, under the identifier NCT00667225, and received
approval from the Institutional Review Board of The University of North Carolina at Chapel
Hill (UNC). Use of cantharidin also required an FDA Investigational New Drug application
and number, obtained in 2007. Participating families received a $10 gas gift card at each
visit.
Dosal et al. Page 2























Patients were recruited from local pediatrician’s offices, UNC Pediatrics Clinic, UNC
Dermatology Clinic, and from mass emails to UNC students and staff during December
2007 to June 2009. Patients were included if 5–10 years of age and had a clinical diagnosis
of molluscum contagiosum (confirmed by the principle investigators). There was no limit on
duration of disease before enrollment. We excluded patients with immunosuppression such
as HIV infection, organ transplantation, or use of immunosuppressive medications,
including oral corticosteroids. Inhaled steroid use was not an exclusion criterion. Patients
previously treated with cantharidin were excluded. Patients with only facial lesions were
also excluded, as current convention discourages use of cantharidin on the face. Females that
had reached menarche were excluded since the effects of cantharidin use in pregnancy have
never been evaluated.
Study design
As approved by UNC’s Internal Review Board (IRB) and the General Clinical Research
Center (GCRC), the study protocol specified a target sample size of 30 children with
complete data for 5 visits spanning 8 weeks. The intended 8-week length of the study was
chosen based on anecdotal experience and logistical considerations; specifically, the study
was designed to be conducted within a specific twelve month period in which funding and
personnel were available. Primary considerations in choosing the target sample size, and the
number of longitudinal evaluations (visits) included the availability of subjects, cost and
time requirements, the anticipated precision of statistical estimators of interest, and
reasonable conjectures about statistical power levels of a pair of hypothesis tests (interim
and final) comparing rates of treatment success. The conjectures about statistical power were
derived from rough estimates of efficacy based only on anecdotal experience, as there was
no relevant data in the literature. The primary consideration in choosing the parallel-arm
experimental design, rather than a crossover design, was immunologic: it is plausible that
the irritation and blister caused by cantharidin (and not the vehicle) could attract
inflammatory mediators and thereby have persisting systemic effects.
Randomization and Blinding
The eligible enrolled patients were assigned at random to cantharidin or placebo. With
assistance from UNC’s Investigational Drug Service, the patients, parents, and investigators
were blind to treatment assignment. The randomization schedule was computed prior to first
recruitment using the method permuted blocks of size two. The randomization was stratified
on self-reported history of atopic dermatitis (AD) because AD was considered to be a known
risk factor for molluscum contagiosum infection. Randomization was 1:1 within each of the
two strata.
Investigational drug
Cantharidin 0.7% was obtained from a local compounding pharmacy (Triangle
Compounding Pharmacy, Cary, NC). It was compounded in a vehicle of acetone,
hydroxypropylcellulose, and flexible colloidon. Serving as a placebo, the vehicle contained
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the same formulation but did not include cantharidin. The vehicle was identical in both
texture and smell. Testing of the vehicle did not produce blisters in investigators.
Study protocol
During visit 1, patients and their parents were consented and eligibility was established.
Subjects and parents then provided information about demographic characteristics and
potential risk factors, including history of dry skin, bathing with siblings/friends, pool use,
and history of AD. The UNC Investigational Drug Service (IDS) then assigned the next
unique subject identification number and dispensed the appropriate drug. Each child was
assigned his or her own bottle (cantharidin or placebo), which was returned to IDS after
each visit. All of the subject’s topical treatments were taken from this bottle.
During each visit, Investigator #1 recorded the number and spatial distribution of all
molluscum lesions (face, trunk, back, left or right arm, left or right leg, hands, feet, buttocks,
groin). All subjects at all visits were examined by this particular investigator in order to
avoid inter-examiner variation. Photographs of the lesions were taken if the patient
consented to photography. Investigator #1 then left the room as Investigator #2 entered the
room to apply the subject’s assigned treatment (cantharidin or vehicle only). A small amount
of medication was applied to the molluscum lesions via the stick end of a cotton-tipped
applicator, with care not to apply to normal skin. Treatment was never applied to any lesions
on the face. To allow the preparation to dry, the children were required to wait about 5
minutes before leaving with parents.
During visit 1, only one or two lesions were treated in order to screen for allergy or
sensitivity to the preparation. In subsequent visits, up to 20 lesions were treated. Parents
were instructed to wash the treated areas 4 hours after application.
Subjects and parents were asked to return for follow-up visits every 1–2 weeks for a
maximum of 5 visits. During each visit, Investigator #2 asked if the child had developed any
blisters, pain, or inflammation. This information was kept hidden from Investigator #1,
whom performed the counting of lesions in subjects, as to not bias the lesion count. All
molluscum lesions were counted, including new lesions.
Statistical Analysis Strategy
Evaluation of efficacy and safety comprised a final analysis using data from all subjects and
an interim analysis based on the first ten patients completing the study.
For analysis of safety, simple tabular listings were used.
Efficacy was evaluated in terms of the total count of lesions observed longitudinally. The
primary null hypothesis to be tested in the interim analysis (α = 0.001) and the final analysis
(α = 0.049) was “cantharidin and placebo do not differ in regard to the incidence rate of
complete clearance of MC lesions by visit 5.” The two treatments were also compared in
terms of the trajectory of longitudinal improvement in the lesion count. This analysis relied
on statistical models supported by simple graphical figures.a In support of the primary
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efficacy results, auxiliary analyses were performed to evaluate the robustness of those
results to reasonable perturbations of the statistical methods and assumptions.b
Secondary aims of the study included exploration of patient characteristics as potential
predictors of baseline log10 lesion count, or as predictors of the magnitude of cantharidin
effects (if any). These exploratory analyses relied on linear statistical models and descriptive
tabular and graphical statistical methods.
All statistical computations were performed using SAS System Software (version 9.2, SAS
Institute, Cary, NC.)
Results
A total of 29 children were enrolled and randomized: 13 assigned to cantharidin, 16 assigned
to placebo via block randomization. The 13:16 allocation imbalance (6:7 in the AD stratum,
7:9 in the non-AD stratum) was due to drop-out. Two of the patients randomized were
subsequently excluded when it was discovered that they did not meet all eligibility criteria.
As the reasons for exclusion were unrelated to treatment-response, the allocation imbalance
did not bias the study.
Table 1 describes the distribution of patient-specific characteristics. These distributions were
generally well-balanced between the two groups, with the exception of subjective history of
“dry skin” being more common in the cantharidin group. Figure 1 illustrates the distribution
of age (years) and self-reported duration of MC infection at visit 1 revealing some
confounding of these two variables.
Median elapsed time between visits 1 and 5 (or final visit) was 8.0 weeks for cantharidin and
7.5 weeks for placebo. Most subjects (12 children in each group) were treated and followed
for 7.0 – 9.0 weeks. (Figure 2)
All but two subjects completed five visits. Both children were female: one was assigned to
placebo, had no lesions at visit 3 (at 8.0 weeks), and did not return for visits 4 and 5; the
other subject was assigned to cantharidin and unaccountably did not return after visit 4 (at
7.7 weeks).
aThe primary model was a linear mixed-effects model20 for the response, log10(count+1). The regression equation expressed mean
response as a treatment-specific linear function of time (represented by visit number 1,2,3,4,5). The model accounted for serial
correlation by including a subject-specific random effect. Statistical estimates of the regression coefficients (β1, β2, β3, β4), the serial
correlation coefficient (ρ), and the total variance (σ2) were obtained by fitting the model to the final data. Those statistical estimates
were used to compute treatment-specific estimates of the population mean response at each visit and the rate of improvement in mean
response, along with corresponding estimates of group differences. All estimates were tabulated along with their 95% confidence
intervals (CI).
bThis sensitivity analysis included numerous variations on the linear mixed-effects model in regard to the following: variance-
covariance assumptions, handling of missing values, choice of temporal index (visit number or elapsed time in weeks), choice of
baseline covariates and interaction terms included, and choice of dependent variable. The sensitivity analyses also included
approaches focusing on the counts at visit 5; e.g., a Wilcoxon two-sample test procedure. As appropriate for count data, various log-
linear models fitted via GEE methods were also examined. The only role of these auxiliary analyses was to guide our level of
confidence in the primary efficacy results by verifying that the primary efficacy results were not sensitive to the choice of methods
and assumptions.
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Interim Analysis of Relative Efficacy and Safety
An interim analysis of the first 10 subjects (5 per group) did not unblind the identities of the
two treatment arms and did not unblind patient assignments. Average age was 7.3 years,
average duration of disease at visit 1 was 8.8 months, and 7 of the 10 children were females.
At visit 1 the number of lesions per patient ranged from 3 to 204 with a median of 17.5.
Efficacy—In terms of the primary endpoint, the performances of the two treatment
regimens were identical as none of the 10 children experienced complete clearance by visit
5. By visit 5, the median lesion count (and CI) for the cantharidin group was 8 [1, 106],
representing an improvement of 41% [−56%, 100%], while the median count (and CI) for
the placebo group was 18 [5, 111], representing an 8% [−66%, 90%] improvement. The
difference of the two medians was 10 [−84, 81]. The extremely wide confidence intervals
around the 41% and 8% indicate that the numerical difference between 41% and 8% is not
meaningful.
Safety—The first 10 subjects experienced no adverse events associated with treatments.
Final Analysis of Relative Efficacy and Safety
Efficacy—The longitudinal counts per child (Figure 2) decreased for 85% of those given
cantharidin and 75% of those given placebo. Complete clearance of lesions by visit 5 was
experienced by few: 15% (2/13) with CI [0%, 35%] for cantharidin, 6% (1/16) with CI [0%,
18%] for placebo. The difference between the two rates of complete clearance was 9% with
CI [−16%, 36%] and two-sided p-value = 0.99. The one-sided 95% upper confidence limit
was 30%. The two groups were similar in the number of subjects who had 0 or 1 lesions on
their final visit: 23% (3/13) with CI [5%, 54%] for cantharidin, 19% (3/16) with CI [4%,
46%] for placebo, and difference 4% with 95% CI [−23%, 34%]. The longitudinal trajectory
of MC toward eventual clearance is characterized by Figure 3 and Table 2 in terms of mean
response on the log10 count scale and in terms of median count. The entries in Table 2 were
obtained by fitting a linear mixed-effects model for log10 count. This model provided
estimates and inferences about the visit-to-visit rate of change: for cantharidin the rate of
−0.17 logs per visit corresponds to a median count decrease of about 32% per visit, while for
placebo the rate estimate of −0.10 corresponds to median decrease of about 21% per visit.
The difference between the two rates was −0.07 with CI [−0.19, 0.05] (p-value = 0.24). If
the intended primary null hypothesis had been “cantharidin and placebo are not different
with respect to rate of change in mean response”, the test of that hypothesis would not be
statistically significant.
Auxiliary analyses demonstrated that these efficacy results were not sensitive to the choice
of statistical methods and assumptions used.
Safety—Pain was reported by 23% (3/13) of cantharidin-treated children and by 6% (1/16)
of placebo-treated children. The difference was 17% with CI [−10%, 44%]. Blistering
(Table 3) was reported by 92% (12/13) CI [67%, 99%] of cantharidin-treated children, and
by 50% (8/16) CI [28%, 72%] of placebo-treated children. The difference between these two
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incidence rates was 42% with CI [9%, 65%] and p-value = 0.02. Six patients reported hypo-
or hyperpigmentation after treatment, all of which were in the cantharidin group.
Exploratory Analyses—Patient characteristics recorded at baseline are listed in Table 1.
It is plausible that some of these nine variables may be predictive of baseline lesion count;
however, such predictive value was not detected. It is also plausible that some of the nine
variables may be predictive of the rate of clearance of lesions. In exploratory analyses, such
predictive value was detected only for age (years). Figure 4 illustrates the apparent
relationship between age and rate of change in the log10 count per week. This result suggests
the hypothesis that cantharidin may have efficacy that depends on the age of the child; i.e.,
efficacy increasing with age, or with increasing age and duration which are partially
confounded together (Figure 1).
Discussion
Previous literature has noted the commonplace use of cantharidin in pediatric dermatology
practice.18 Parents19 and practitioners3 have reported satisfaction with results achieved with
cantharidin. In a previous retrospective review of a similar patient population, the average
time to molluscum clearance was 2.3 months using monthly follow-up visits.19 Our 2-month
study aimed to quantify cantharidin’s efficacy compared to vehicle. To our knowledge, there
have been no other vehicle controlled randomized trials evaluating cantharidin’s efficacy.
In this randomized, 2-month, placebo-controlled clinical trial, the performance of
cantharidin was observed to be similar to that of placebo. In terms of the temporal rate of
improvement in median lesion count, the estimated rate for cantharidin was 32% fewer
lesions per visit, while the estimated rate for placebo was 21% fewer lesions per visit. The
primary hypothesis test of efficacy was inconclusive (i.e., not statistically significant.) This
test procedure does not, and cannot, establish that cantharidin has zero efficacy. Although
the hypothesis test was inconclusive, the point estimates and confidence intervals do provide
information about the plausible range of the magnitude of efficacy. In terms of complete
clearance of lesions by visit 5, the observed treatment success rate was 15% (2/13) for
cantharidin patients and 6% (1/16) for placebo, yielding an observed difference being 9%
with CI [−16%, 36%]. The confidence interval suggests that it is plausible that the true
magnitude of difference is in the range of −16% to 36%. It also suggests that it is unlikely
that the true difference is as large as anecdotal and retrospective reports have suggested.
Cathcart et al19 noted that 54% (29/54) of cantharidin-treated patients reported subjective
complete clearance when treated for about 2 months. Silverberg et al13 reported that 95% of
parents of cantharidin-treated patients stated that they would proceed with cantharidin
treatment again. A possible explanation for the contrast between our study and these
retrospective studies is the preciseness and strictness of our definition of clearance.
Additionally, parents may look back favorably on their treatment with cantharidin even
without complete resolution of all lesions. If this is the case, then there may be some recall
bias and over-estimation of clearance. Additionally, there may be some pressure to please
investigators in a telephone survey and potential for inflation of satisfaction.
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In secondary analyses we explored self-reported patient characteristics as potential risk
factors for poor outcomes and as predictors of lesion count at baseline. The exploratory
results suggested a new hypothesis: the biological effects and relative efficacy of cantharidin
may depend on the age of the child; specifically, increasing efficacy with increasing age.
Self-reported patient characteristics of interest included previously inflamed lesions.
Molluscum lesions that exhibit irritation or inflammation are classically thought to be
nearing spontaneous resolution. It has been hypothesized that a “switch” occurs when the
immune system starts to recognize an individual focus of molluscum virus, gathers
inflammatory cells and mediators in the area, and soon thereafter clears the virus with
subsequent disappearance of the lesion. We did not detect any association between lesion
clearance and prior history of irritated, inflamed, or previously resolved lesions.
For the immunologic reasons cited above, we did not choose to use a crossover study design.
The irritation and blister caused by cantharidin (and not with the vehicle) could theoretically
attract inflammatory mediators and possibly speed the resolution of untreated or vehicle-
treated lesions, via the hypothesis outlined above.
Blistering was self-reported and not observed by the physician, as blistering typically
occurred at home after the patient encounter. As expected, almost all (92%) cantharidin-
treated subjects reported blistering. The substantial number of placebo-treated subjects that
reported blistering (50%) was surprising. However, this blistering was not confirmed by the
investigators – it is our sense that patients may have interpreted the colloidon membrane
from the vehicle as a blsiter. There may be some recall bias in patients’ self reporting as
well. Finally, the sometimes surprisingly-strong placebo effect should not be discounted..
None of the ingredients in the vehicle preparation are known to have blister-inducing
properties.
No patients dropped out due to side effects. The most common side effects were local
irritation and blistering with cantharidin. Six cantharidin and no vehicle patients reported
pigmentary change. We suspect this is due to post-inflammatory pigment alteration that is
comparable to other destructive techniques, however subjects were not followed for longer
than 8 weeks to assess duration of the pigmentary change.
Pain was reported by 6% of placebo-treated patients, and 23% (3/13) of cantharidin-treated
subjects; e.g., one experienced pain when scrubbing off the medication. The 23% rate is
much lower than would be seen with other destructive techniques, and the discomfort is
delayed until after the patient leaves the office. This allows for non-traumatic treatment of
molluscum and preservation of the relationship and trust between the dermatologist and
child. Our results demonstrate that when used correctly, cantharidin can be used with
minimal side effects.
This study characterized longitudinal improvement in total lesion counts during 8 weeks of
treatment. Anecdotal experience and previously published retrospective reviews suggested
an expectation that roughly half of cantharidin-treated subjects would experience complete
clearance of lesions. This study was not designed to address the longitudinal course of MC
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beyond the first 8 weeks of treatment, which could potentially capture a greater efficacy of
cantharidin – further studies would be needed to investigate this theory.
The target sample size, 30, was chosen based on considerations of the availability of
subjects, cost and time requirements, the anticipated precision of statistical estimators of
interest, and reasonable conjectures about statistical power levels of a pair of hypothesis
tests (interim and final) comparing rates of treatment success. The conjectures about
statistical power were derived from rough estimates of efficacy based only on anecdotal
experience, as there was no relevant data in the literature.
Enrollment of 30 subjects was surprisingly difficult. Families were reluctant to enroll their
child in a study that had a 50% risk of being assigned to placebo when they could decline
participation and receive verified cantharidin in the regular clinic.
An important aspect of our study design was the stratification of atopic dermatitis patients.
Future studies involving patients with molluscum contagiosum should control for atopic
status because other studies have demonstrated that they tend to have a more prolonged and
severe course.
It is possible that the two treatment groups were not balanced with respect to other important
factors in spite of randomization. For example, we do not know how many subjects in each
group were patients on the verge of spontaneous remission; consequently, it might be
conjectured that there were more “spontaneous resolvers” in the placebo arm of the study.
However, clearance was infrequent in both arms: neither arm of the study experienced the
higher rates of complete clearance that had been expected based on anecdotal experience
and previous retrospective observational reports.
We do know that the subjects assigned to placebo had had their MC lesions for 8.5 months,
on average, while the average duration for cantharidin-treated subjects only 6 months. The
longer the lesions are present the better the chance for spontaneous remission. However,
clearance was infrequent even in the placebo arm. Furthermore, the primary efficacy results
were invariant to whether or not duration of MC was taken into account as a covariate.
The interim analysis demonstrated, as did the final analysis, that (1) the “complete
clearance” endpoint is a poor summary variable in this context, (2) characterization of the
longitudinal trajectory of lesion counts is more informative, and (3) that the counts follow
distributions that are approximately log-normal. In contrast to the “complete clearance”
endpoint, endpoints defined in terms of interval-scale measures of the decrease in lesion
count offer more powerful tests of efficacy hypotheses.
This study serves as a platform for future studies investigating tools for the treatment of
molluscum contagiosum. It has provided objective unbiased estimates of the magnitude of
cantharidin treatment effects and of variance and correlation, has contributed important
prospective safety data, and it has generated a new hypothesis about age-dependent efficacy.
If the relative efficacy of cantharidin is small compared to placebo, than in future studies a
larger sample size may be warranted.
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The value of our study is it can help future studies better assess the efficacy of cantharidin in
molluscum contagiosum. In addition, the clinician is informed that almost weekly
application of cantharidin to molluscum lesions over a span of 8 weeks does not have
statistically improved benefit over placebo. Our institution has patients willing to come on a
weekly basis to clear the virus from their homes; we can confidently inform them that
weekly visits are not necessary. Based on our anecdotal experience, we still believe
cantharidin is useful and safe in the treatment of childhood molluscum contagiosum and are
in favor of further studies with a larger sample size and longer duration.
We conclude that in our study the magnitude of the cantharidin treatment effect in the target
population was, at best, not large during the 2 month study period: the temporal rate of
clearance of lesions and the incidence of complete clearance of all lesions were not
dramatically different from that achieved with placebo. We also conclude that cantharidin
can be used with minimal side effects and is safe in children when used properly.
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At visit 1, duration of MC infection (weeks) was moderately confounded with age (years).
The coefficient of correlation between age and log10(duration) was r = 0.42 with 95% CI
[0.06, 0.68]. Values plotted are for subjects assigned to cantharidin (solid dots) and for
subjects assigned to placebo (open circles).
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The individual-specific lesion counts in log10 scale for each treatment group. As a visual aid,
each nonparametric smooth curve descibes the trajectory for an individual child. The
temporal index is Weeks. Only 3 subjects experienced complete clearance (squared symbol
plotted at “1 or 0”). Two other subjects (placebo) has 1 lesion at visit 5. Another subject
(cantharidin, age 5) had only 1 lesion at visit 3, but 6 lesions at visit 5.
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For cantharidin (●) and for placebo (⊕), visit-specific sample means (left) and sample
medians (right) are shown with their corresponding 95% confidence intervals.
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Rate of change in log10(count) per week was computed for each child by linear regression.
Rate = 0 indicates the count did not change, while Rate = −0.5 indicates a rapid decrease in
lesion count. For cantharidin (solid dots), the coefficient of correlation between Age (yrs)
and Rate of change (per week) was r = −0.57 with 95% CI [−0.85, −0.03]. For placebo r =
0.01 with 95% CI [−0.49, 0.50].
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Flow diagram of participant progress throughout the trial.
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Table 1
Distribution of Patient Characteristics of Interests
Cantharidin Placebo
N=13 N=16
% Female 62% (8/13) 63% (10/16)
% Self-Reported Dry Skin 67% (8/12)* 38% (6/16)
% Self-Reported Atopic Dermatitis History 46% (6/13) 44% (7/16)
% Reported History of Inflamed Lesions 25% (3/12)* 19% (3/16)
% Reported Resolution of some Lesions Prior to Study 42% (5/12)* 44% (7/16)
% Reported Bathing with Siblings 45% (6/13) 38% (6/16)
% Reported Frequent Swimming Pool Use 77% (10/13) 81% (13/16)
Age in Years at Visit 1: mean (standard deviation) 6.7 (1.8) 7.3 (1.7)
Duration of MC in Months at Visit 1: median (range) 6.0 (0–24) 8.5 (2–24)
Weeks of treatment and follow-up: median (range) 8.0 (4.6–8.3) 7.5 (5.0–11.0)
*
The missing data all come from the same subject.
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